Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipients.

Tornatore KM, Sudchada P, Attwood K, Wilding GE, Gundroo AC, DiFrancesco R, Gray V, Venuto RC.

J Clin Pharmacol. 2013 Mar;53(3):285-93. doi: 10.1177/0091270012447814. Epub 2013 Jan 24.

PMID:
23444283
2.

Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients.

de Winter BC, van Gelder T, Glander P, Cattaneo D, Tedesco-Silva H, Neumann I, Hilbrands L, van Hest RM, Pescovitz MD, Budde K, Mathot RA.

Clin Pharmacokinet. 2008;47(12):827-38. doi: 10.2165/0003088-200847120-00007.

PMID:
19026038
3.

Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.

Arns W, Breuer S, Choudhury S, Taccard G, Lee J, Binder V, Roettele J, Schmouder R.

Clin Transplant. 2005 Apr;19(2):199-206.

PMID:
15740555
4.

Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.

Budde K, Glander P, Krämer BK, Fischer W, Hoffmann U, Bauer S, Grohmann J, Neumayer HH, Arns W.

Transplantation. 2007 Feb 27;83(4):417-24.

PMID:
17318074
5.

Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.

Capone D, Tarantino G, Kadilli I, Polichetti G, Basile V, Federico S, Sabbatini M.

Nephrol Dial Transplant. 2011 Sep;26(9):3019-25. doi: 10.1093/ndt/gfq819. Epub 2011 Feb 11.

6.

Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.

Djabarouti S, Duffau P, Lazaro E, Chapouly C, Greib C, Viallard JF, Pellegrin JL, Saux MC, Breilh D.

Expert Opin Pharmacother. 2010 Apr;11(5):689-99. doi: 10.1517/14656561003592144.

PMID:
20210680
7.

Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients.

Tedesco-Silva H, Felipe CR, Park SI, Pinheiro-Machado PG, Garcia R, Slade A, Schmouder R, Medina-Pestana JO.

Clin Transplant. 2010 Jul-Aug;24(4):E116-23. doi: 10.1111/j.1399-0012.2009.01183.x.

PMID:
20047618
8.

Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.

Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D.

Transplant Rev (Orlando). 2011 Apr;25(2):47-57. doi: 10.1016/j.trre.2010.06.001. Epub 2010 Dec 28.

PMID:
21190834
9.

Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.

Hummel M, Yonan N, Ross H, Miller LW, Sechaud R, Balez S, Koelle EU, Gerosa G; ERL 2401 Study Group.

Clin Transplant. 2007 Jan-Feb;21(1):18-23.

PMID:
17302587
10.
11.

Evaluation of mycophenolic acid exposure using a limited sampling strategy in renal transplant recipients.

Li J, Liu Y, Huang J, Fu Q, Chen E, Liu L, Zhang R, Huang M, Wang C.

Am J Nephrol. 2013;37(6):534-40. doi: 10.1159/000351180. Epub 2013 May 15.

PMID:
23689735
12.

Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study.

Yin H, Qiu K, Hu XP, Li XB, Wang W, Liu LH, Zhang XD.

Int J Clin Pract Suppl. 2014 Apr;(181):31-7. doi: 10.1111/ijcp.12404.

PMID:
24673717
13.

Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.

Tedesco-Silva H, Bastien MC, Choi L, Felipe C, Campestrini J, Picard F, Schmouder R.

Transplant Proc. 2005 Mar;37(2):852-5.

PMID:
15848554
15.

Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft.

Neumann I, Fuhrmann H, Kanzler M, Fang IF, Jaeger A, Graf H, Bayer P, Kovarik J.

Expert Opin Pharmacother. 2008 Apr;9(6):879-86. doi: 10.1517/14656566.9.6.879.

PMID:
18377332
16.

Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.

Sánchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Conesa J, Barrientos A.

Transplant Proc. 2007 Sep;39(7):2194-6.

PMID:
17889135
17.

Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation.

Belliere J, Esposito L, Gandia P, Duffas JP, Sallusto F, Cardeau-Desangles I, Del Bello A, Rostaing L, Kamar N.

Ann Transplant. 2014 Feb 10;19:76-81. doi: 10.12659/AOT.889691.

18.

Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients.

Tornatore KM, Sudchada P, Dole K, DiFrancesco R, Leca N, Gundroo AC, Danison RT, Attwood K, Wilding GE, Zack J, Forrest A, Venuto RC.

J Clin Pharmacol. 2011 Aug;51(8):1213-22. doi: 10.1177/0091270010382909. Epub 2011 Jan 5.

PMID:
21209244
19.

Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients.

Tornatore KM, Meaney CJ, Wilding GE, Chang SS, Gundroo A, Cooper LM, Gray V, Shin K, Fetterly GJ, Prey J, Clark K, Venuto RC.

Clin Pharmacokinet. 2015 Apr;54(4):423-34. doi: 10.1007/s40262-014-0213-7.

20.

Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.

Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, Neumayer HH.

Transplant Proc. 2004 Mar;36(2 Suppl):524S-527S.

PMID:
15041401
Items per page

Supplemental Content

Write to the Help Desk